Equities

Tonix Pharmaceuticals Holding Corp

TNXP:NAQ

Tonix Pharmaceuticals Holding Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1499
  • Today's Change0.005 / 3.31%
  • Shares traded538.26k
  • 1 Year change-99.45%
  • Beta2.1006
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Tonix Pharmaceuticals Holding Corp have a median target of 11.00, with a high estimate of 48.00 and a low estimate of 4.00. The median estimate represents a 7,238.23% increase from the last price of 0.1499.
High31,921.3%48.00
Med7,238.2%11.00
Low2,568.4%4.00

Earnings history & estimates in USD

On Aug 16, 2024, Tonix Pharmaceuticals Holding Corp reported 2nd quarter 2024 losses of -19.28 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-17.73%
Tonix Pharmaceuticals Holding Corp reported annual 2023 losses of -219.20 per share on Apr 01, 2024.
Average growth rate+69.27%
More ▼

Revenue history & estimates in USD

Tonix Pharmaceuticals Holding Corp. had 2nd quarter 2024 revenues of 2.21m. This missed the 3.50m consensus estimate of the 3 analysts following the company.
Average growth rate-16.88%
Tonix Pharmaceuticals Holding Corp. had revenues for the full year 2023 of 7.77m.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.